News & Events
Published On: 4/14/2020
TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
Now Largest Real-World Evidence Nonalcoholic Fatty Liver Disease Study in the World
TARGET PharmaSolutions, a real-world clinical data company, today announced that its nonalcoholic fatty liver disease (NAFLD) study, TARGET-NASH, reached 5,000 enrolled patients. TARGET-NASH is now the largest active observational and longitudinal NASH-specific study in the world.
“TARGET-NASH has reached 5,000 enrolled patients in only its fourth year of data collection,” said TARGET PharmaSolutions CEO, Neal Bibeau. “This regulatory-grade data is providing tremendous insight about the burden of the disease and is accelerating our partners’ understanding of these patients and the most effective strategies to bring innovative solutions to treat the disease.”
TARGET-NASH is an observational study of participants diagnosed with nonalcoholic fatty liver (NAFL) and/or NASH. The network of TARGET clinical sites includes both community and academic centers and enrolls adult and pediatric participants across the spectrum of the disease. Once enrolled, three years of retrospective data and five years of prospective data is collected from study participants, including patient-reported outcome measures and biorepository samples.
TARGET-NASH was the first disease community established by TARGET when the company launched in 2015. Since then, TARGET has developed six additional communities including hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), and most recently, TARGET-ASTHMA.
To create each real-world community, the TARGET model organizes groups of stakeholders around specific diseases to produce regulatory-grade data and analysis on the disease’s natural history, current treatment paradigms, and patient outcomes. Stakeholders includes key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups who are involved in answering critical strategic and planning questions.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
03/01/2021Andrew von Eschenbach, M.D. Joins Target RWE as Senior Advisor
02/22/2021TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy
02/02/2021Target RWE Shares Weight Loss Data From Ongoing NASH Study
01/15/2021Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
12/21/2020TARGET-HCC Initial Manuscript Published in Hepatology Communications